IL13RA2 and neoplasm: Unfortunately, disease recurrence was observed after 7.5 months with tumor formation in new locations and decreased expression of IL13Rα2, elucidating a common antigen loss response to targeted therapies and advocating for rational combinational or adjuvant therapies.